LONDON – Renovo plc is weighing its options, including that of winding up the company, after its lead scar-improving product Juvista failed in the pivotal Phase III European trial. Shares (LSE:RNVO) in the Manchester, UK-based company fell 75 percent to 17 pence when the news was announced on Friday afternoon.